Xvivo Perfusion AB
21.80
USD
-1.05
(-4.60%)
ISIN
SE0004840718
Return %
Stock
S&P 500
1Y
14.42
14.20
3Y
-13.49
81.12
5Y
-54.83
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Christoffer Rosenblad
- Full Time Employees
- 210
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- MAessans gata 10 Mölndal VG Sweden 431 53
- IPO Date
- Oct 8, 2012
- Website
- xvivogroup.com
- Similar Companies
- Business
- Xvivo Perfusion AB (publ) (XVIVO.ST) develops, manufactures, and markets perfusion technology solutions for organ transplantation and preservation worldwide. The company offers a comprehensive portfolio of products and services, including organ-specific perfusion machines such as the Heart Assist Transport device for heart preservation, the Liver Assist device for liver perfusion, and the Kidney Assist Transport for kidney preservation; preservation solutions like the proprietary VitriSol cryopreservation medium, Steen Solution for lung ex vivo perfusion, and PermaSol for machine perfusion; and associated services encompassing clinical training, regulatory support, and maintenance programs for transplant centers. Xvivo Perfusion operates primarily in the biotechnology and medtech sectors, targeting organ transplant professionals, hospitals, and research institutions across Europe, North America, and Asia-Pacific, with headquarters in Gothenburg, Sweden, where it was founded in 1989 as a spin-off from Chalmers University of Technology. In recent developments, the company expanded its offerings through the launch of next-generation Heart Assist Transport XX in 2024, enhancing transport capabilities for donor hearts with improved normothermic perfusion features; it also secured CE Mark approval for its PermaSol preservation solution in Europe and initiated U.S. FDA clinical trials for the same product in late 2024. Xvivo Perfusion strengthened its market position via a strategic distribution partnership with OrganOx in 2025 for liver perfusion technologies in select regions and completed the acquisition of certain assets from a U.S.-based biopreservation firm in early 2025 to bolster its cryopreservation portfolio. Additionally, the company announced a major funding round in mid-2025, raising SEK 500 million through a rights issue to support global expansion and R&D investments in lung and thoracic organ technologies. These initiatives reflect Xvivo Perfusion's ongoing shift toward integrated, end-to-end organ recovery ecosystems amid growing demand for machine perfusion in solid organ transplantation.
Company News
Xvivo Perfusion AB (publ) (XVIPY) Q2 2026 Earnings Call Transcript
Bulletin from Annual General Meeting in XVIVO Perfusion AB (publ)
Xvivo Perfusion AB (publ) (XVIPY) Q1 2026 Earnings Call Transcript
Notice To Attend the Annual General Meeting in XVIVO Perfusion Ab (Publ)
The Nomination Committee of XVIVO Perfusion AB (publ) Proposes Emil Billbäck and Anne-Karen Hunt as New Members of the Board of Directors
Xvivo Perfusion AB (publ) (XVIPY) Q4 2025 Earnings Call Transcript
Xvivo Perfusion AB (publ) (XVIPY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript